Artisan Partners Limited Partnership Buys 73,452 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Artisan Partners Limited Partnership increased its holdings in Akero Therapeutics, Inc. (NASDAQ:AKROFree Report) by 30.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 311,036 shares of the company’s stock after purchasing an additional 73,452 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.56% of Akero Therapeutics worth $15,732,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of AKRO. Swiss National Bank boosted its position in Akero Therapeutics by 7.8% during the first quarter. Swiss National Bank now owns 37,100 shares of the company’s stock valued at $526,000 after acquiring an additional 2,700 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Akero Therapeutics by 3.5% during the first quarter. Bank of New York Mellon Corp now owns 81,582 shares of the company’s stock valued at $1,157,000 after acquiring an additional 2,793 shares during the last quarter. MetLife Investment Management LLC boosted its position in Akero Therapeutics by 58.5% during the first quarter. MetLife Investment Management LLC now owns 15,580 shares of the company’s stock valued at $221,000 after acquiring an additional 5,750 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Akero Therapeutics by 33.9% during the first quarter. Dimensional Fund Advisors LP now owns 337,790 shares of the company’s stock valued at $4,794,000 after acquiring an additional 85,525 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Akero Therapeutics by 4.8% during the first quarter. Vanguard Group Inc. now owns 1,226,911 shares of the company’s stock valued at $17,410,000 after acquiring an additional 56,492 shares during the last quarter.

Akero Therapeutics Price Performance

AKRO stock opened at $19.76 on Friday. The stock has a market capitalization of $1.10 billion, a PE ratio of -8.41 and a beta of -0.43. The company’s 50-day moving average is $21.69 and its 200-day moving average is $29.42. The company has a debt-to-equity ratio of 0.04, a current ratio of 20.25 and a quick ratio of 20.25. Akero Therapeutics, Inc. has a 1 year low of $11.25 and a 1 year high of $58.38.

Insider Transactions at Akero Therapeutics

In related news, Director G. Walmsley Graham acquired 50,000 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were bought at an average price of $16.90 per share, with a total value of $845,000.00. Following the transaction, the director now directly owns 650,000 shares of the company’s stock, valued at $10,985,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, COO Jonathan Young sold 30,000 shares of the company’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $14.68, for a total value of $440,400.00. Following the sale, the chief operating officer now owns 153,177 shares in the company, valued at approximately $2,248,638.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director G. Walmsley Graham bought 50,000 shares of the stock in a transaction that occurred on Thursday, November 30th. The stock was acquired at an average price of $16.90 per share, for a total transaction of $845,000.00. Following the acquisition, the director now directly owns 650,000 shares in the company, valued at $10,985,000. The disclosure for this purchase can be found here. Insiders have sold 59,071 shares of company stock valued at $1,046,321 in the last 90 days. 9.69% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Akero Therapeutics in a research report on Tuesday, November 14th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $40.86.

Check Out Our Latest Report on AKRO

Akero Therapeutics Company Profile

(Free Report)

Akero Therapeutics, Inc, a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.

Read More

Institutional Ownership by Quarter for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.